Overview

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of ALKS33-BUP when administered to opioid-experienced cocaine abusers.
Phase:
Phase 1
Details
Lead Sponsor:
Alkermes, Inc.
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
ALKS-33
Buprenorphine
Cocaine